Articles tagged with Ovarian Cancer
A novel method for monitoring on-treatment disease burden in high-grade serous ovarian cancer uses tumor-informed breakpoints-spanning ddPCR, detecting superior sensitivity and specificity compared to real-time PCR. The approach may enable sensitive and specific detection of minimal residual disease and early relapse detection.
Researchers mapped PARP inhibitors' distribution using advanced imaging techniques and patient ovarian tumour samples, revealing that build-up of drugs in lysosomes can trap and release certain drugs over time. This mechanism increases exposure to cancer cells, leading to variable treatment responses.
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
Researchers at UC San Diego discover a new way to re-educate the immune system to attack ovarian cancer tumors by blocking protein FAK. The study offers hope for developing better treatments by turning the tumor environment from immune-suppressing to immune-activating.
The novel approach outperforms standard CAR-T cell therapy in preclinical studies using mouse models of glioblastoma and ovarian cancer. Armored CAR-T cells eliminate tumors, reshape the tumor environment, and boost immune-cell activity.
Researchers at Linköping University have developed an AI-boosted electronic nose that can detect ovarian cancer from blood plasma samples with high accuracy. The method uses machine learning to identify patterns specific to the disease, making it a promising tool for early detection and improved survival rates.
A Phase II study presents significant overall survival benefits for women with platinum-resistant ovarian cancer treated with elenagen plus gemcitabine. Longer exposure to elenagen correlates with longer survival after treatment discontinuation, suggesting a fundamentally different therapeutic approach.
Ovarian cancer cells recruit protective mesothelial cells in abdominal fluid to form hybrid cell clusters that resist chemotherapy. These clusters use spike-like structures called invadopodia to invade surrounding tissue. The discovery opens new treatment possibilities and could help doctors monitor disease progression.
A study published in JAMA found that salpingectomy significantly lowers the risk of developing tubo-ovarian carcinoma. The procedure, typically performed during unrelated pelvic or abdominal surgery, is now recommended as a preventive measure for eligible women.
A new study confirms that opportunistic salpingectomy (OS), which involves removing fallopian tubes during hysterectomy or tubal ligation, reduces the risk of serous ovarian cancer by nearly 80%. The procedure leaves ovaries intact, preserving hormone production and minimizing side effects.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Five IIT researchers receive Proof-of-Concept grants to develop innovative health technologies, including a smart microscope and edible pills. These projects aim to tackle cancer, dyslexia, and diagnostics with cutting-edge technologies like quantum computing and near-infrared photonic chips.
Melanie Rutkowski's pioneering research may lead to novel immunotherapy treatments for ovarian cancer by understanding how faulty cellular signaling interacts with the microbiome. The grant aims to enhance immune system's ability to kill cancer cells and improve patient outcomes.
Researchers found that ovarian cancer transforms the omentum into an environment that favors tumor spread. The study analyzed tissue samples from 15 patients and created a cell atlas of the omentum in diseased and healthy states.
A new study validates OVCAR3 as a reliable model for high-grade serous ovarian carcinoma, providing insights into disease behavior and potential therapeutic targets. The research also explores the effects of repurposed drugs on ovarian cancer cells, revealing promising results for treatment responses.
UT Health San Antonio received $3 million in CPRIT grants to expand access to preventive salpingectomy, test novel methods to prevent liver cancer, and advance treatment for therapy-resistant metastatic breast cancer. These projects aim to improve cancer prevention, diagnosis, and treatment in South Texas.
Studies show that patients with advanced ovarian and metastatic breast cancer dedicate approximately 7 hours per week to cancer-related tasks. Most participants report performing these tasks daily, impacting their time burden. The use of a mobile app facilitated the collection of detailed time-use data.
Lab studies found that a combination of THC and CBD kills ovarian cancer cells without harming healthy cells. The compounds may prevent metastasis and have minimal toxic effects, making them a promising alternative to current treatments.
Sofetabart mipitecan, a novel ADC targeting folate receptor alpha, shows robust clinical activity in patients with platinum-resistant ovarian cancer. The GOG-3133/ FRAmework-01 phase 3 study aims to expand treatment options for recurrent ovarian cancer and address the need for more effective therapies.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
Researchers have identified a protein complex that drives T cell exhaustion in tumors and show that disrupting it can revive exhausted anti-tumor CTLs. The study's findings offer new hope for improving the efficacy of cancer immunotherapy.
Australian scientists have developed a new blood test that can identify women with ovarian cancer more likely to benefit from PARP inhibitor therapy, offering hope for more effective treatment. The test measures immune biomarkers and predicts which patients will respond to treatment.
MIT researchers have developed new nanoparticles that deliver the immune-stimulating molecule IL-12 directly to ovarian tumors, eliciting a strong response and clearing tumors in over 80% of mice. This treatment combines with checkpoint inhibitors to launch an attack on cancer cells without causing side effects.
Scientists have identified a new biomarker, F2R, which could improve ovarian cancer diagnosis and treatment. Elevated F2R levels are associated with shorter life spans, making it a valuable prognostic indicator.
A major study of breast, cervical, and ovarian cancers found significant inequalities in global care, with many low- and middle-income countries (LMICs) diagnosing cancer at a later stage. Surgery was offered consistently, but treatment consistency varied, with LMICs often choosing mastectomy over breast-conserving surgery.
Black and Asian patients were underrepresented in clinical trials, leading to worse survival outcomes compared to white counterparts, despite similar progression-free survival rates. Equitable enrollment is crucial for access to cutting-edge treatments and long-term equity in cancer care.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
MSK researchers have developed a new method to study treatment resistance in high-grade serous ovarian cancer. By analyzing blood samples from 18 patients, they identified subpopulations of cancer cells with distinctive genetic features that contribute to recurrence. This approach may help develop targeted treatments for specific vulne...
The loss of Trp53 leads to more aggressive tumor growth and weaker immune responses in ovarian cancer. Researchers developed a mouse model that mimics human HGSC, showing how the disease progresses and evades the immune system.
Researchers identified NBL1 as a key driver of ovarian cancer metastasis through its activation of the Jak/Stat3 pathway. NBL1 expression levels strongly correlated with advanced clinical stage and poor survival outcomes.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
Researchers developed Ovatools, a tool combining blood test results and age to identify women at higher risk of ovarian cancer. The approach is accurate for women over 50 and represents good value for the NHS, detecting more cancers earlier while remaining within affordability thresholds.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
A 36-year-old woman was diagnosed with non-gestational ovarian choriocarcinoma, a rare and aggressive tumor that shares symptoms with pregnancy. She received chemotherapy and showed complete response to treatment.
A significant proportion of patients with high-grade serous ovarian cancer missed genetic testing and surgical prevention opportunities due to limited effective screening options and treatment limitations. The study emphasizes the importance of addressing these gaps to eradicate this aggressive form of ovarian cancer.
Researchers identify three tumor-reactive T cell subpopulations that exhibit selective expansion in ovarian cancer patients. CD8+ TCF7-expressing Tpex cells demonstrate self-renewal capacity and generate stem-like progenies, which may enhance persistence and specificity in current TIL therapy.
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
A 23-year bibliometric analysis reveals key hotspots in ovarian cancer care, including quality of life, surgery, and nursing health. The study emphasizes the need for future research on psychological well-being and integrated care models to improve outcomes for women with ovarian cancer.
Researchers developed a novel radioimmunotherapy that successfully eliminated cancer stem cells (CSCs) in preclinical models of ovarian cancer. The therapy, targeting CSC-associated biomarkers L1CAM + /CD133 + , showed significantly increased cytotoxicity compared to existing treatments.
A study of ovarian tumor immune landscapes reveals four distinct immunologic subtypes, with those with T cells surviving longer and having better outcomes. The researchers also found that myeloid cells play a key role in reestablishing the immune landscape upon recurrence.
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
A new study found that over 65% of ovarian cancer tumors exhibit whole-genome doubling, making them more resistant to treatments. WGD-high tumors suppress the immune response by repressing key pathways.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
A team led by University of Houston engineer Tianfu Wu aims to find better biomarkers for ovarian cancer using autoantibodies and machine learning. By detecting ovarian cancer earlier, mortality rates could be reduced by 10-30%.
A retrospective analysis of 22 patients with brain metastases from ovarian cancer treated with Gamma Knife stereotactic radiosurgery (GKSRS) showed a high intracranial tumor control rate of 97.1% at 12 months post-treatment. No acute or chronic toxicity was observed in the study.
A new combination treatment strategy selectively targets ovarian tumor cells, reducing growth in preclinical models. The approach identifies effective regimens to treat genetically diverse cancers by blocking specific growth signaling pathways.
A new genetic marker, PPP2R1A mutations, has been linked to improved survival rates for patients treated with immunotherapy in ovarian and other cancers. Targeting this biomarker may further enhance treatment outcomes, suggesting a potential new therapeutic target.
Researchers employed a novel validation-based insertional mutagenesis technique to identify genes conferring carboplatin resistance in human epithelial ovarian cancer cells. HN1L was found to enhance resistance by activating NF-κB signaling, and targeting this gene may represent a promising strategy for overcoming platinum resistance.
Mayo Clinic researchers have detected early, hidden changes in cells lining a patient's fallopian tubes, revealing signals that may point to the first signs of ovarian cancer. The study uses cutting-edge single-cell technologies to uncover developmental alterations in epithelial cells that signal high risk for lethal ovarian cancer.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.
A new study explains how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma, a rare and aggressive form of ovarian cancer. Researchers discovered that inactivating CDK12 triggers an immune cell response and identified a partner gene, CDK13, as a target for a degrader or inhibitor.
The ESMO Gynaecological Cancers Congress 2025 will convene in Vienna, Austria, from June 19-21, featuring novel data on immunotherapy combinations and emerging treatment strategies for rare gynaecological cancers. The congress will also explore innovative approaches using antibody-drug conjugates.
Researchers discovered that blocking PRDX1 protein can make ovarian cancer cells more responsive to DNA-damaging platinum therapies. The study suggests targeting PRDX1 could be a viable strategy to improve chemotherapy efficacy.
Weill Cornell Medicine researchers Dr. Juan R. Cubillos-Ruiz and Dr. David Lyden have been awarded a $750,000 grant to study ovarian cancer, with a focus on harnessing immune cells and detecting the disease earlier. Their research aims to develop innovative strategies for eliminating metastatic tumors and preventing recurrence.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
Researchers found that phospholipids in ascites fluid disrupt immune cell function, particularly NK cells, leading to impaired anti-tumor activity. Blocking these lipids can restore NK cell activity, providing a promising therapeutic target.
A study found that removing ovaries and fallopian tubes in women with BRCA1 and BRCA2 genetic variants significantly reduces the risk of early death from cancer. This procedure, known as bilateral salpingo-oophorectomy (BSO), also decreases the risk of developing a second cancer without any serious side effects.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.